Fundraising Fox

Collegium Pharmaceutical

NASDAQ: COLL

Canton, US · Virginia corporation · 488 employees on LinkedIn · 4 known investors

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.

Founders & leadership

MH
Michael HeffernanFounder
PB
Paul BrannellyExecutive

Board

EN
Eran NadavBoard director
JF
John FreundBoard director
PHPatrick Heron
Patrick HeroninBoard Member2008–2016Managing Partner at Frazier Life Sciences
DH
David HirschBoard director
PF
Patrick FortuneBoard director
SH
Stephen HoffmanBoard director
GSGino Santini
Gino SantiniBoard director
GBGaren Bohlin
Garen BohlinBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$92.5M disclosed across 3 rounds · 2012–2018

$20MraisedNov 2018 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael HeffernanDirector
  • David HirschDirector
  • Garen BohlinDirector
  • Shirley KuhlmannExecutive Officer
  • Theodore SchroederDirector
  • John A FallonDirector
  • Alison B. FlemingExecutive Officer
  • Gwen MelincoffDirector
  • Gino SantiniDirector
  • Scott DreyerExecutive Officer
  • Joseph CiaffoniExecutive Officer, Director
  • John FreundDirector
  • Paul BrannellyExecutive Officer
Offering amount
$20M
Amount sold
$20M
First sale
Nov 2018
Incorporated
Corporation, Virginia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$50MraisedMar 2015 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gino SantiniDirector
  • Eran NadavDirector
  • John FreundDirector
  • Patrick HeronDirector
  • Garen BohlinDirector
  • David HirschDirector
  • Michael HeffernanExecutive Officer, Director
  • Paul BrannellyExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Mar 2015
Incorporated
Corporation, Virginia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$22.5MraisedFeb 2012 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David HirschDirector
  • Patrick HeronDirector
  • Patrick FortuneDirector
  • Michael HeffernanExecutive Officer, Director
  • Stephen HoffmanDirector
Offering amount
$22.5M
Amount sold
$22.5M
First sale
Feb 2012
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Collegium Pharmaceutical for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$472.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Collegium Pharmaceutical do?
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Who founded Collegium Pharmaceutical?
Collegium Pharmaceutical was founded by Michael Heffernan.
Who are Collegium Pharmaceutical's investors?
Collegium Pharmaceutical's investors include APERTURE Venture Partners, EcoR1 Capital, Frazier Life Sciences, Longitude Capital.
How much funding has Collegium Pharmaceutical raised?
Collegium Pharmaceutical has disclosed $92.5M raised across 3 rounds.
Where is Collegium Pharmaceutical headquartered?
Collegium Pharmaceutical is headquartered in Canton, US.